The Priority Review

Tag

UROCOM-R2

1 story

  1. Clinical trials

    Il-Yang Pharm. Co. registers Phase 3 trial of UROCOM-R1 plus UROCOM-R2

    The study plans to enroll 660 participants and is expected to start on November 9, 2026. It plans to compare the efficacy and safety of UROCOM-R1 plus UROCOM-R2 combination therapy with UROCOM-R1 or UROCOM-R2 monotherapy in patients with benign prostatic hyperplasia.